STOCK TITAN
  1. Home
  2. News
  3. TAK

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of - TAK STOCK NEWS

Welcome to our dedicated page for Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of stock.

Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.

With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.

Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.

Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.

Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.

News

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Rhea-AI Summary
Takeda gains approval for ADZYNMA, a groundbreaking treatment for congenital thrombotic thrombocytopenic purpura (cTTP) in Japan. ADZYNMA is the first recombinant ADAMTS13 enzyme replacement therapy for cTTP, addressing acute events and chronic symptoms. The approval is based on positive interim analysis results from a Phase 3 trial, showcasing efficacy, safety, and tolerability. ADZYNMA demonstrated a significant reduction in acute TTP events compared to plasma-based therapies, with a lower incidence of treatment-related adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
News

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Rhea-AI Summary
Takeda's ICLUSIG receives FDA approval as the first targeted treatment for frontline Ph+ Acute Lymphoblastic Leukemia in the U.S., showing superior results in MRD-negative Complete Remission rates compared to imatinib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
fda approval
-
News

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Rhea-AI Summary
Takeda announces positive Phase 2 results for mezagitamab in patients with primary immune thrombocytopenia, showing safety, tolerability, and efficacy. Plans for a global Phase 3 trial in fiscal year 2024. Mezagitamab demonstrates promising platelet response rates and potential disease remission in ITP patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
clinical trial
News

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Rhea-AI Summary
Takeda and Biological E. Limited form a strategic partnership to accelerate the manufacturing of QDENGA, a Dengue Tetravalent Vaccine, in multi-dose vials. The collaboration aims to provide up to 50 million doses per year by BE, supporting Takeda's goal of delivering 100 million doses annually by 2030. Dengue poses a significant global health threat, with increasing incidence rates worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
News

FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)

Rhea-AI Summary
Takeda's EOHILIA Receives FDA Approval for Eosinophilic Esophagitis Treatment, Offering Relief to Patients 11 Years and Older
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
fda approval
-
News

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Rhea-AI Summary
Takeda announces positive topline results from a Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1. The trial demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8. TAK-861 was found to be generally safe and well-tolerated, with no treatment-related serious adverse events reported. Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 rapidly in the first half of its fiscal year 2024. The results have no impact on the full-year consolidated reported forecast for the fiscal year ending March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
earnings clinical trial
News

Takeda Announces Chief Financial Officer Succession

Rhea-AI Summary
Takeda announces the departure of CFO Costa Saroukos, effective April 1, 2024, with Milano Furuta set to succeed him. Saroukos has played a key role in Takeda's transformation and the successful acquisition of Shire PLC. Furuta, with a strong financial background and global experience, is well-equipped to lead Takeda's finance organization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
-
News

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

Rhea-AI Summary
Takeda announced two new U.S. FDA approvals in FY2023 Q3 for FRUZAQLA and ADZYNMA, enhancing its portfolio. The company reported a revenue growth of +4.6% at AER, flat at CER, and a core operating profit change of -12.7% at CER. Takeda's financial results show a strong momentum in its Growth & Launch Products, offsetting the revenue impact of generic entrants. The company remains on track towards its full-year Management Guidance, reflecting significant generic impact, lower coronavirus vaccines revenue, and investment in R&D and data, digital, and technology to secure long-term competitiveness. Takeda's Chief Financial Officer, Costa Saroukos, emphasized the company's vision to discover and deliver life-transforming treatments and the improvement in their debt profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
earnings
-
News

Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Rhea-AI Summary
Takeda has received FDA approval for GAMMAGARD LIQUID as an intravenous immunoglobulin therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This milestone follows the recent FDA approval of HYQVIA for maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults with CIDP. The approval is based on results from a prospective, open-label, single-arm, multicenter clinical study that evaluated the efficacy and safety of GAMMAGARD LIQUID in adults with CIDP who developed a relapse in the randomized, double-blinded, placebo-controlled study evaluating efficacy, safety, and tolerability of HYQVIA in adults with CIDP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
News

Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Rhea-AI Summary
Takeda's HYQVIA has been approved by the European Commission for the treatment of chronic inflammatory demyelinating polyneuropathy, offering patients a once-monthly maintenance therapy option. The approval expands Takeda's portfolio of immunoglobulin therapies for patients with neuroimmunological disorders. The approval is based on a Phase 3 trial that showed a significant reduction in CIDP relapse rate with HYQVIA versus placebo, with a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none

FAQ

What is the current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?

The current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK) is $13.38 as of November 22, 2024.

What is the market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?

The market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK) is approximately 42.4B.

What are Takeda Pharmaceutical's core therapeutic areas?

Takeda focuses on oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

Where is Takeda Pharmaceutical headquartered?

Takeda is headquartered in Tokyo, Japan.

What recent collaborations has Takeda Pharmaceutical entered into?

Takeda recently entered a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation to incubate early drug discovery programs.

How diversified is Takeda's revenue geographically?

Takeda's revenue is geographically diversified: 50% from the US, 20% from Japan, and 20% from Europe and Canada.

What was Takeda's revenue in fiscal 2023?

Takeda's revenue in fiscal 2023 was JPY 4.3 trillion.

Who can benefit from Takeda's new drug NBI-1065845?

NBI-1065845 is targeted at patients with major depressive disorder who have not benefited from at least one existing antidepressant treatment.

What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?

The joint venture focuses on incubating early drug discovery programs to advance academic discoveries into practical medical treatments.

How long has Takeda been in the pharmaceutical industry?

Takeda has been a leader in the pharmaceutical industry for over two centuries.

In how many countries does Takeda operate?

Takeda operates in approximately 80 countries.

How does Takeda contribute to the field of major depressive disorder treatment?

Takeda collaborates with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment showing positive Phase 2 results for MDD.

Stock TAK logo
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of

NYSE:TAK

TAK Rankings

#322 Ranked by Market Cap
#654 Ranked by Dividends

TAK Stock Data

42.40B
3.17B
0.01%
2.45%
0.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Tokyo